What is the purpose of the SPARTA study?
The goal of the SPARTA study is to learn if an investigational drug, called APL-101, can help patients with non-small cell lung cancer (NSCLC) or other advanced solid tumors with a genetic alteration in c-Met oncogene (such as amplification, fusion, or EXON 14 skipping mutation). Other advanced solid tumors include, but are not limited to, brain, head and neck, gastric, esophageal, biliary, pancreatic, or colorectal cancer.
The SPARTA study is sponsored by Apollomics, Inc.
Who can take part in the SPARTA study?
You may be able to participate in the SPARTA study if you meet the following requirements:
- Are at least 18 years of age or older
- Been diagnosed with NSCLC or another advanced solid tumor with an altered c-Met pathway
- Have not received standard cancer therapy or received standard cancer therapy that is no longer effective or is causing too many side effects
Other requirements will apply. Complete the pre-screener to find out if you meet preliminary qualification requirements.
What can study participants expect?
Study participation may last for up to 12 months or longer. During this time, participants can expect the following:
Receive health assessments to find out if you qualify for the SPARTA study.
Take the study drug twice daily, by mouth, in 28-day cycles for as long as the participant is benefiting from it.
Attend study clinic visits about once a month while taking the study drug to receive health assessments.
Check in with the study staff 30 days after you stop taking the study drug to check your general health.
Receive follow-up from the study staff every 3 months after you stop taking the study drug. They will check if you have started new cancer therapies.